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Introduction
Since the first implants of heterologous tissue valve prostheses in 
the 1960s, improvements in tissue valve design and manufacturing 
have been implemented. Tissue valves have central flow and a 
high freedom from thrombus formation and usually do not need 
anticoagulation treatment. However, most tissue valves originate 
from biologic materials that undergo degenerative processes.1)2) A 
study of the causes of valve failure leading to reoperation reported 
that sterile degeneration or primary tissue failure accounted for 74% 
of bioprosthetic valve failures.3) Degeneration of biologic heart valve 
prostheses is believed to depend on the mechanical properties of the 
valve and on immunologic and calcification processes.4) Similarities 
between the mechanisms and risk factors for atherosclerosis, native 
valve calcification and postoperative tissue valve degeneration have 
recently been proposed.5)6) A chronic inflammatory change in the 
valve leaflet, including infiltration of macrophages and T lymphocytes 
and lipoprotein deposition in the areas of calcification, has prompted 
investigation as to whether medical therapy can be applied to slow the 
progression of valve failure.
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Background and Objectives: There are pathophysiologic similarities between calcification and atherosclerosis because both are the product of 
an active inflammatory process. The aim of this study was to examine the effects of statin treatment on calcification in bovine pericardial 
tissue valves. 
Materials and Methods: Forty Sprague-Dawley rats were randomly divided into 4 groups according to hypercholesterolemia induction and 
statin intake (Group 1, n=10: normal diet without statin treatment, Group 2, n=10: normal diet with statin treatment, Group 3, n=10: high 
fat diet without statin treatment, Group 4, n=10: high fat diet with statin treatment). Serum lipid levels were measured just before the 
experiment and after 4 and 12 weeks. Bovine pericardial tissue valve cusps were surgically implanted in rat dorsal subcutis at 4 weeks. After 
the surgery, statin was administered daily to Groups 2 and 4. Serum interleukin-6 (IL-6) level was measured at 5 weeks. Cusps were explanted 
at 12 weeks and calcium levels were determined by atomic absorption spectroscopy.
Results: Mean IL-6 was significantly higher in Group 3 at 5 weeks (7.14, 2.03, 31.70, and 6.90 pg/dL for each group, respectively). Mean 
calcium level in Group 3 was significantly higher among groups but Group 4 was significantly lower compared to Group 3 and was similar to 
Group 1, 2 (1.86, 1.92, 2.55, and 1.80 mg/g for each group, respectively, p<0.01).
Conclusion: Hypercholesterolemia may be a significant risk factor for bovine pericardial valve calcification. Statin treatment significantly 
attenuated calcification of bovine pericardial valve tissue in a rat subdermal implantation model and might prolong the durability of 
bioprostheses.  (Korean Circ J 2017;47(3):401-408)
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This question has driven new research into prevention and treatment 
for postoperative valve tissue failure. A few studies have shown that 
the use of statins reduced calcific degeneration of native aortic 
valves.7-9) A few retrospective clinical series have also shown the 
potential relationship between statins and tissue prosthetic valves for 
preventing the progression of bioprosthetic valve degeneration.10)11) 
However, to our knowledge few studies have prospectively analyzed 
the effects of statin treatment on structural changes to biological 
tissue in prosthetic cardiac valve substitutes. Therefore, the aim of this 
study was to evaluate the effects of a specific statin therapy, namely 
rosuvastatin (Crestor®, HMG-CoA reductase inhibitors, rosuvastatin 
calcium, AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA), on 
post-implant tissue changes to commonly used bovine pericardial 
tissue valve in a rat subdermal implantation model.
Material and Methods
Animals, diets, and experimental design
This animal study was approved by the Institutional Animal Care 
and Use Committee of Yonsei University Health System (publication 
no. 2014-0365, 2014).
Healthy 2 month old Sprague-Dawley rats (n=40) weighing 
380.27±13.68 g were used in the present study. The animals were 
acclimatized for a week. Then, they were divided into four groups 
according to hypercholesterolemia induction and rosuvastatin intake 
(n=10): (1) Group 1, normal diet without statin treatment; (2) Group 2, 
normal diet with statin treatment; (3) Group 3, high cholesterol diet 
without statin treatment; (4) Group 4, high cholesterol diet with statin 
treatment. Group 1 and 2 were fed a normal diet for 12 weeks and 
Group 3 and 4 were fed a diet containing 1.25% cholesterol and 0.5% 
cholic acid (TD.02028, Harlan Korea Laboratories Co., Ltd, Seoul, Korea) 
for 12 weeks. All other conditions were kept the same for each group.
Measurement of blood lipid profile and interleukin-6 level
Non-fasting blood lipid profile (triglyceride, total cholesterol 
[Tchol], and low density lipoprotein [LDL] cholesterol) were measured 
just before the experiment and after 4 and 12 weeks for validation 
of proper hypercholesterolemia. For blood collection, the animals 
were anesthetized with 10 mg/kg of xylazine and 30 mg/kg of Zoletil® 
(Virbac Philippines Inc., Taguig, Philippines). Then, 1.3 mL of blood was 
aseptically obtained from the subclavian vein and 0.5mL of blood 
was placed into a heparin tube and another 0.8 mL of blood was 
placed into a serum separating tube. Plasma samples were obtained 
by centrifugation at 6000 rpm for 5 min at room temperature. TG, LDL 
cholesterol, and TC were measured by enzymatic colorimetric assay 
(Modular analytics, Roche, Germany). Serum samples were obtained 
by centrifugation at 14000 rpm for 10 min at 4°C and stored at 
-70°C in a deep freezer until further analysis. Serum Il-6 levels were 
measured at 5 and 12 weeks using enzyme-linked immunosorbent 
assay kits (Quantikine®, Rat IL-6 Immunoassay kit, R&D Systems, 
MN, USA). 
Animal experiment
Commercially available bovine pericardial bioprosthetic heart 
valves (BHVs; Carpentier-Edward PERIMOUNT Aortic valve®, Edwards 
Lifesciences LLC, Irvine, CA, USA) were used in this study. Each BHV 
was rinsed at least 15 minutes with 500 mL of sterile physiological 
saline solution and transferred to another rinse basin with sterile 
saline. Each leaflet was then incised along the frame of the BHV using 
a no.11 surgical blade. Then, a round shaped patch was made using a 
4 mm skin biopsy punch (Fig. 1A).
At 4 weeks after hypercholesterolemia induction, the patch was 
surgically implanted in rat dorsal subcutis. Briefly, each animal was 
intraperitoneally injected with 10 mg/kg of xylazine, and 30 mg/kg of 
Zoletil® (Virbac Philippines Inc., Taguig, Philippines). After placing an 
animal in a ventral recumbent position, a dorsal midline skin incision 
was made. Then, four trimmed pericardial patches were implanted 
subcutaneously and fixed with 6-0 polypropylene sutures (Fig. 1B). 
The subcutaneous layer was sutured with a simple continuous pattern 
using 5-0 polyglyconate sutures, and the skin was closed with a simple 
interrupted pattern using 4-0 nylon. For three days after surgery, 
20 mg/kg of gentamicin and 1 mg/kg of meloxicam were injected 
subcutaneously for infection prophylaxis and analgesia, respectively.
From the day after surgery, 20 mg/kg/day of rosuvastatin in 2 mL 
of normal saline was given to Groups 2 and 4 animals by oral gavage 
using an 18 gauge feeding tube with adequate restraint for 8 weeks. 
Body weight was measured every week to update drug dosage. Group 
1 and 3 animals were given 2 mL of normal saline only.
Fig. 1. Valve patch implantation model in rat. (A) Implant preparation. 
Round shaped implant (small box) was made using skin biopsy punch. 
(B) Gross appearance after patch implantation. 
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Quantitative calcium determination
Eight weeks after surgery, animals were euthanized by the 
CO2 inhalation method and implanted samples were collected. A 
Perkin Elmer Optima 8300 ICP-OES (Norwalk, CT, USA) was used 
for implant calcium analysis. For ICP-OES analysis, surrounding 
connective tissue from the implants was cleanly removed then frozen 
for 24 hours in a -80°C deep freezer. After removing moisture for 
24 hours using a freezing dryer, samples were weighed and then 
dissolved in 5 mL of aqua regia in a 100-mL beaker. After adding 5 mL 
of hydrogen peroxide (H2O2), the beaker was slowly heated on a 
hot plate for 6 hours at 70-80°C (to dissolve the tissue) and for 
5 h at 140-150°C; 5 mL of H2O2 were then added. After adjusting 
the volume up to 50 mL, the samples were analyzed by ICP-OES.
Histopathological evaluations
Samples were fixed in 10% neutralized buffered formalin (BBC 
Biochemical, WA, USA) and processed using standard methods then 
embedded in paraffin. The 4-μm-thick sections were stained with 
hematoxylin (Sigma-Aldrich, MO, USA) and eosin (BBC Biochemical, 
WA, USA) (H&E). The count of infiltrated cells within the implants 
was performed blindly by an objective pathologist. Eight pictures of 
each sample were obtained at x400 magnification and were used for 
the cell count.
Western blot analysis
To investigate the expression of BMP-2, and osteopontin (OPN), 
samples were stored at -70°C in a deep freezer. Protein was extracted 
with 500 uL of PRO-PREP® protein extraction solution (Intron 
Biotechnology, Seongnam, Korea), followed by tissue homogenization 
using sharp scissors. After 30 minutes on ice, samples were centrifuged 
at 4°C, 14000 rpm for 10 minutes. Then, the supernatant containing 
the protein lysates was collected.
Quantification of protein content was performed with a Protein-
assay Kit (Bio-rad, CA, USA). For immunoblotting, each 50 µg of 
total protein extract was mixed with Laemmli sample buffer and 
transferred to a Mini Protean® TGX™ precast gradient gel (Bio-rad, 
CA, USA) with DOKDO-MARK™ (Intron Biotechnology, Seoungnam, 
Korea) as a standard pre-stained protein marker. Gel electrophoresis 
was performed with a Mini Protean® system (Bio-rad, CA, USA) 
applying 100 V for 130 minutes. After electrophoresis, proteins were 
blotted to a methanol pre-activated PVDF membrane applying 230 
mAh for 90 minutes using a Mini Trans-Blot® Cell (Bio-Rad, CA, USA). 
Blotted membranes were then blocked and incubated with anti-BMP-2 
antibody (ab6285, 1:1000 dilution, Abcam, Cambridge, UK) and anti-
OPN antibody (ab8448, 1:1000 dilution, Abcam, Cambridge, UK) in PBS-T 
with 5% skimmed milk. Anti-β-actin antibody was used as a loading 
control (ADI-905-733, 1:2000 dilution, Enzo Lifescience, NY, USA). After 
incubation with the primary antibodies, membranes were washed with 
PBS-T buffer three times and then incubated with secondary goat 
anti-mouse IgG-HRP (ab6789, 1:2000 dilution, Abcam, Cambridge, UK) 
for anti-BMP-2 antibody and anti-OPN antibody and goat anti-rabbit 
IgG-HRP (ADI-SAB-300-J, 1:2000 dilution, Enzo Lifescience, NY, USA) 
for anti-β-actin antibody. Proteins were detected using an enhanced 
chemiluminescence (ECL) detection reagent for immunoblot analysis 
(Daeill Lab Service, Seoul, Korea). Subsequently, quantitative analysis 
was performed with the pixel density analysis method using Image J 
software (National Institutes of Health, NY, USA). Relatively density was 
defined as follows: (specific band density/β-actin band density)×100.
Statistical analyses
All data are expressed as mean±standard deviation. Statistical analyses 
Fig. 2. Blood lipid profiles. Blood Tchol level and LDL level were significantly 
increased in the hypercholesterol diet intake group. In addition, rosuvastatin 
significantly lowered Tchol and LDL levels in hypercholesterolemic rats. (A) 
Blood Tchol level just before experiment, (B) blood LDL level just before 
experiment, (C) blood Tchol level at 4 weeks, (D) blood LDL level at 4 weeks, 
(E) blood Tchol level at 12 weeks, (F) blood LDL level at 12 weeks. ***p<0.001, 
###p<0.001 when compared with other groups, †††p<0.001 when compared 
with Group 3. NS: not significant, Tchol: total cholesterol, LDL: low density 
lipoprotein cholesterol.
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were performed using GraphPad Prism 5.0 software (GraphPad Software, 
Inc., San Diego, CA, USA).  Normal data distribution was determined 
using the Shapiro-Wilk test. One-way ANOVA and post hoc Bonferroni 
tests were used to compare mean blood lipid and Il-6 levels, and the 
relative density of Western blotting level between groups. Kruskal-Wallis 
and Mann-Whitney tests were applied to assess overall/pair-wise group 
mean differences in calcium level and nucleated cell count between 
groups. A p value<0.05 was considered statistically significant.
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Fig. 3. Effect of rosuvastatin on blood Il-6 level and calcium level in the bovine pericardial implant. Rosuvastatin significantly lowered Il-6 level within 1 week 
after surgery. In addition, rosuvastatin significantly decreased calcium level in hypercholesterolemic animals. (A) Il-6 level at 5 weeks, (B) Il-6 level at 12 weeks, 
(C) calcium level at 12 weeks. *p<0.05 when compared with other groups, †p<0.05 when compared with group 3. Il-6: interleukin-6.
A  B  C  
Table 1. Data summary for each experimental group
Experiment model
Group 1 Group 2 Group 3 Group 4
ND+saline ND+statin HC+saline HC+statin
Body weight (g)
Pre 379.53±15.46 383.78±13.88 383.12±8.33 374.20±15.21
4 weeks 474.20±17.13 485.66±30.10 506.58±18.79 488.61±25.71
12 weeks 576.61±24.08 589.54±38.13 621.59±42.88 606.06±37.28
Blood profiles
Tchol (mg/dL)
Pre 71.56±10.32 67.00±10.23 69.44±9.57 71.00±13.27
4 weeks 69.75±9.21 76.00±11.64 231.38±86.88‡ 250.75±35.34‡
12 weeks 81.88±8.13 81.88±10.30 241.13±58.65‡ 156.00±32.14ll
LDL (mg/dL)
Pre 11.33±2.65 11.33±4.30 12.22±3.11 12.00±3.39
4 weeks 9.00±2.83 9.50±2.93 181.63±77.87‡ 194.00±25.29‡
12 weeks 17.00±3.30 16.25±3.33 183.63±54.25‡ 103.38±26.83ll
Il-6 (pg/dL)
5 weeks 7.14±6.24 2.04±3.53 31.70±13.40* 6.90±11.32§
12 weeks 25.72±9.30 23.49±6.50 60.44±29.27 48.83±22.36
Calcium level (mg/g) 1.86±0.35 1.92±0.22 2.55±0.74* 1.80±0.25§
Infiltrate cell counts (cells) 127.65±45.06 81.05±28.55 190.13±74.75† 71.95±43.47ll
Relative band density (%)
OPN 42.80±6.67 41.72±5.04 97.39±7.75† 53.94±5.98§
BMP-2 85.16±25.10 60.42±12.34 198.69±52.88† 81.73±22.74ll
*p<0.05 compared with other groups, †p<0.01 compared with other groups, ‡p<0.001 compared with other groups, §p<0.05 compared with Group 3, 
llp<0.001 compared with Group 3. ND: normal diet, HC: hypercholesterolemic diet, Tchol: total cholesterol, LDL: low density lipoprotein cholesterol, Il-6: 
interleukin-6, OPN: osteopontin, BMP-2: bone morphogenic protein-2
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Results
Effect of statin treatment on blood lipid profiles, Il-6 level, 
and body weight
Rosuvastatin significantly reduced blood Tchol levels in 
hypercholesterolemic animals (Table 1). Tchol levels measured just 
before the experiment were not significantly different between 
each group (Fig. 2A). However, Tchol levels at 4 weeks in Groups 
3 and 4 were significantly higher than those in Groups 1 and 2 
(p<0.001, Fig. 2C). In addition, Tchol level at 12 weeks in Group 4 was 
significantly lower than that in Group 3 (p<0.001, Fig. 2E). The effect 
of rosuvastatin on blood LDL cholesterol level was also similar. The 
LDL cholesterol levels at 4 weeks in Groups 3 and 4 were significantly 
higher than those in Groups 1 and 2 (p<0.001, Fig. 2D), but Group 4 was 
significantly lower than that of Group 3 at 12 weeks (p<0.001, Fig. 2F). 
Il-6 level at 5 weeks in Group 3 was significantly higher than Groups 1 
(p=0.0012) and 2 (p=0.0012) (Fig. 3A). Il-6 level at 5 weeks in Group 4 
was significantly lower than that of Group 3 (p=0.0282, Fig. 3A). There 
were no statistically significant differences between Groups 1, 2, and 4. 
The Il-6 level in Group 3 showed the highest average value at 12 weeks, 
but there were no statistically significant differences between the Groups 
(Fig. 3B). Rosuvastatin did not affect the animals’ body weight change. All 
of the animals gained weight every week but there were no significant 
differences between groups (Table 1). 
Effect of statin treatment on implant calcium level
The calcium level was detected in all samples 12 weeks after 
implantation. The calcium level of Group 3 was significantly higher 
than Groups 1 (p=0.0246) and 2 (p=0.0240) (Fig. 3C). There was 
no significant difference in calcium level in the normal diet groups 
(Group 1 vs. Group 2) regardless of rosuvastatin administration 
(p=0.62, Fig. 3C). However, rosuvastatin treatment significantly 
decreased calcium levels in the hypercholesterolemic groups 
(p=0.0041, Fig. 3C).
Effect of statin treatment on cellular infiltration into 
bovine pericardial implants
Rosuvastatin significantly reduced cellular infiltration into bovine 
pericardial implants in hypercholesterolemic animals. Microscopic 
examination showed the implants had stacked eosinophilic collagen 
fibers (Fig. 4). Numerous cellular infiltrates were predominantly 
presented around the implants and some of them were also present 
within the fibers of the implants. Highest cellular infiltrates were 
observed in Group 3. In the normal diet groups, infiltrated cell counts 
for Group 2 were significantly lower than Group 1 (p=0.0014, Fig. 4E). 
Group 4 infiltrate cell count was significantly lower than Groups 1 
(p<0.01) and 3 (p<0.001) (Fig. 4E). There was no statistical difference 
between Groups 2 and 4 (p=0.1641). 
Effect of statin treatment on expression of proteins 
involved in calcification metabolism
The relative band density of each group is presented in Table 1. 
Western blotting showed that BMP-2 and OPN expressions were 
significantly increased in hypercholesterolemic animals, Groups 
3 and 4 (Fig. 5). However, rosuvastatin significantly suppressed 
BMP-2 (p<0.05) and OPN (p<0.01) expression in Group 4 compared 
to Group 3. There was no significant difference between the 
rosuvastatin and normal diet groups. 
Discussion 
This study investigated the effect of rosuvastatin on bovine 
Fig. 4. Histopathological analysis. Cellular infiltration was significantly 
reduced in rosuvastatin-treated groups. (A) Microscopic image of Group 1, 
(B) microscopic image of Group 2, (C) microscopic image of Group 3, (D) 
microscopic image of Group 4, (E) graph of nucleated cell count results. 
(hematoxylin and eosin stain, x200 magnifi cation) *p<0.05 when compared 
with Group 1, **p<0.01 when compared with Group 1, †††p<0.001 when 
compared with Group 3.
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pericardial aortic tissue valve calcification in a rat subdermal 
implantation model. The principal findings of our study were that high 
cholesterol level may be a significant risk factor for bovine pericardial 
valve calcification. Statin treatment could significantly attenuate 
calcification of bovine pericardial valve tissue in a subcutaneous rat 
model with dual anti-calcification and anti-inflammation effects 
regardless of hypercholesterolemia. 
Farivar et al.5) reported for the first time that increased serum 
cholesterol levels were associated with increased bioprosthetic 
valve calcification4. Furthermore, patients who had explanted 
valves showed higher serum cholesterol levels than age-, duration 
of survival-, and position matched patients with unexplanted 
valves (189 vs. 163 mg/dL, p<0.001). Finally, the odds ratio for valve 
explantation was 3.9-fold higher in patients whose serum cholesterol 
levels were greater than 200 mg/dL. Palta et al.10) also demonstrated 
that those with a serum cholesterol level greater than 200 mg/dL 
had a reduced native aortic valve area that was nearly twice that 
of those with a lower cholesterol level (p=0.04). However, Bellamy 
et al.12) recently reported that there was no correlation between the 
rate of aortic stenosis (AS) progression and cholesterol levels in 157 
patients with AS. They insisted that progression of AS showed no 
trend for association with cholesterol level; however, statin treatment 
was associated with slower progression. Statin treatment induced 
a decreased degeneration of the aortic valve. In that study, the 
authors confirmed that AS progressed with a reduction in orifice 
size of approximately 0.1 cm2/year in patients who didn`t receive 
statin therapy. Shavelle and coworkers13) reported that patients 
receiving statins had a reduced accumulation of aortic valve calcium, 
as assessed with electron beam computed tomography, although 
unfortunately serum cholesterol levels were not collected. However, 
all these reports were retrospectively reviewed using human cohort 
comparison studies and the object of the studies was human native 
aortic valves. In addition, experimental studies investigating the 
correlation between bioprosthetic calcification and blood lipid level 
are rare.
Recently, an experimental study using bovine pericardial 
bioprosthesis in a rat subdermal implantation model showed that 
atorvastatin treatment attenuated bioprosthesis calcification along 
with reducing the global extent of inflammatory infiltrates.14) They 
concluded that these effects could enhance structural preservation 
of bioprostheses and diminish calcific deposition. However, the 
correlation between the hypercholesterolemic condition and 
bioprosthetic calcification wasn’t clear because they did not 
observe hypercholesterolemia. However, our experiment showed 
that hypercholesterolemia was clearly associated with bioprosthesis 
calcification. Moreover, our results indicated that statin treatment 
could prevent post-implant calcification and inflammatory infiltration 
even in animals under hypercholesterolemic conditions. However, 
calcification degree was not significantly different between Groups 1 
and 2 in our study, as opposed to Lorusso et al.14)’s report. The major 
predictive factors for this discrepancy could be the differences in 
animal species and follow-up periods between the studies. Short-
term rosuvastatin or long-term atorvastatin studies using the same 
species will help resolve these discrepancies.
The correlation of increased cholesterol levels with bioprosthetic 
valve calcification calls for mechanistic hypotheses.15) Eliminating 
lipids from tissue valves by means of ethanol extraction prevents 
in vivo calcification.16) It is possible that glutaraldehyde-fixed valves 
have the appropriate physical characteristics to serve as a nidus for 
crystallization. Another potential mechanism of calcification is the 
migration of cells into the valve matrix. Blood-borne progenitor cells 
that are capable of differentiating into various lineages might have 
the ability to deposit matrix, which can calcify. Additionally, oxidized 
LDL cholesterol, which interacts with T lymphocytes and calcium, 
has been demonstrated in degenerative aortic valve stenosis.17) In 
those studies, diverse strategies were employed to prevent tissue 
calcification, including inhibitors of hydroxyapatite formation, 
calcium diffusion inhibitors, peculiar material processing methods to 
reduce tissue material to calcification, and improved glutaraldehyde 
or non-glutaraldehyde tissue fixation.6) However, there have been 
few studies investigating post-implant treatment for degeneration 
or calcification inhibition. The hypothesis of pathophysiological 
similarity among atherosclerosis, bioprosthetic, and native valve 
Fig. 5. Expression profiles involved in calcification metabolism. (A) Western 
blot analysis results. OPN and BMP-2 expressions were significantly lower 
in the rosuvastatin-treated group than in the normal saline-treated group 
with hypercholesterolemia. (B) Relative density of BMP-2, (C) relative 
density of OPN. **p<0.01 when compared with other groups, ††p<0.01 
when compared with Group 3. †p<0.05 when compared with Group 3. 
OPN: osteopontin, BMP-2: bone morphogenic protein-2.
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degeneration has recently been suggested and calls for new 
research directions, particularly for novel treatment and prevention 
options.10)11)18) However, the role of hypercholesterolemia in cardiac 
valve degeneration remains unclear. Lorusso et al.14) reported a clear 
reduction in calcium deposition in pericardial tissue explanted from 
animals on statin therapy, either in terms of micro calcification or 
global calcium content. This effect, however, was not linked to a 
hypercholesterolemic state, indicating that calcific degeneration 
might also be induced in the presence of normal levels of cholesterol 
or may be induced by inflammatory or immunological-related 
changes elicited in the host body by the heterologous explant material. 
To clearly show the effect of statin treatment, we classified animals 
into 4 groups according to hypercholesterolemia and statin intake to 
observe the effect of statin treatment on both non-hyperlipidemia and 
hyperlipidemia. Our results showed a strong effect of statin treatment 
for preventing hypercholesterolemia and anti-inflammatory reactions 
that were due to inhibition of cellular infiltrates and IL-6 activation. 
Also, a marked reduction in calcium deposition was found in both 
statin treatment groups and BMP-2 and OPN expressions related 
to calcium metabolism. The pleiotropic effects of statin treatment 
have been recently highlighted19)20) and characterized as immune 
modulation, anti-inflammatory actions, cell proliferation inhibition, 
and a decrease in bone-matrix progenitor cells. In hyperlipidemic 
animal models, Rajamannan et al.21) showed that diet-induced 
atherosclerosis caused typical lesions to native aortic valves, whereas 
the administration of statins in this setting counteracted maladaptive 
valve change, particularly by reducing cellular proliferation and bone 
matrix production, but also by mitigating maladaptive immunological 
responses. Actually, BMP-2 stimulated osteoblastic differentiation. 
Mundy et al.22) recently used high-throughput screening accompanied 
by a BMP-2 gene promotor-driven reporter assay and found that 
statins stimulated the BMP-2 promoter. Statins also increased the 
number of mouse osteoblasts and amount of new bone formed, 
similar to that seen with recombinant BMP-2 itself. However, in our 
experiment, BMP-2 was analyzed in prosthetic valve tissue, not in rat 
blood stream. Statins can strongly inhibit inflammatory mediators 
and reactions such as IL-6. Consequently, this anti-inflammatory 
mechanism might downregulate BMP-2 in valve tissue. Osman et 
al. suggested that human valve ICs (interstitial cells) were capable 
of osteoblastic differentiation by potential mediators which could 
be pharmacologically targeted by statin treatment and statins could 
cause a downregulation in BMP-2 expression levels.23) 
Study limitations and conclusions
The limitations of this study are the small number of experiments 
and tissue implantation in a subcutaneous animal model which is 
different than the circulation model; therefore, our data should be 
interpreted with caution. The resected prosthetic valve cusp is also 
already injured by cutting, so its coating membrane continuity was 
broken before implantation. Thus, this experimental situation might 
induce cellular infiltration from the host system. This could result in 
explant valve inflammation and calcification when compared to un-
resected valve cusps. Finally, the relationship between tissue valve 
calcification mitigation in animal model studies and clinical outcomes 
has not been established. 
In conclusion, high cholesterol level may be a significant risk 
factor for bovine pericardial valve calcification. Statin treatment 
significantly attenuated calcification of bovine pericardial valve tissue 
in a subcutaneous rat model and showed dual anti-calcification and 
anti-inflammation effects regardless of hypercholesterolemia. This 
result suggests we should consider statin treatment to elongate 
bioprosthesis durability.
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